At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 131 enrolled
Drug / intervention
GSK2340272A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years
In Brief
A Phase 3 clinical trial evaluating GSK2340272A and GSK2340269A for Influenza. Completed, enrolled 131 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in adults aged 18 to 60 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesBelgium
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartOct 2009
Primary CompletionOct 2009
Study CompletionOct 2010
TodayJul 2026
First PostedOct 5, 2009
Enrollment StartOct 7, 2009
Primary CompletionOct 9, 2009
Study CompletionOct 26, 2010
TodayJul 2, 2026
Enrollment to primary: 2 daysPosted 16.7 years ago
Interventions
GSK2340272Abiological
Two intramuscular injections in the deltoid region of the non-dominant arm.
GSK2340269Abiological
Two intramuscular injections in the deltoid region of the non-dominant arm.